Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis
Introduction
Multiple sclerosis (MS) is considered as a T cell-mediated autoimmune disease of the central nervous system. Autoreactive T cells are not only found in MS patients, but are part of the normal immune repertoire. Potent regulatory mechanisms such as CD95-mediated apoptosis might contribute to prevent T cell-mediated tissue damage, e.g., in the central nervous system. CD95 is a cytokine receptor which mediates apoptotic cell death when bound by its natural ligand. Increasing evidence suggests a role for apoptosis and the CD95/CD95 ligand system in the pathogenesis of MS (Pender et al., 1991; Schmied et al., 1993; D'Souza et al., 1996; Dowling et al., 1996; Bonetti and Raine, 1997; Dowling et al., 1997). Recently, we and others showed that MS patients with relapsing remitting and active disease have significantly higher soluble serum CD95 levels than patients with inactive disease or controls (Inoue et al., 1997; Zipp et al., 1998). Here, we report that the soluble CD95 in MS sera is functionally active and blocks CD95 ligand-mediated apoptosis in susceptible target cells.
Section snippets
Selection of donors
This study was approved by the University of Tübingen and the National Institute of Neurological Disorders and Stroke (NINDS) Institutional Review Boards. We have previously found that CD95 levels were elevated in a group of 71 patients with relapsing remitting disease. Here, we compared relapsing remitting MS patients with a group of patients with chronic progressive disease course (n=17). All 88 patients had clinically definite MS.
Detection of soluble CD95
CD95 levels in the serum of patients, obtained at time points
Results
Previously reported (Zipp et al., 1998) patients with relapsing remitting disease had significantly higher serum CD95 levels than chronic progressive MS patients (194±45 U/ml vs. 66±37 U/ml) (mean±SEM) (p=0.005). Serum from eight patients with relapsing remitting MS and high CD95 levels and eight patients with chronic progressive disease and low levels were studied for inhibition of apoptosis. First, we used the highly sensitive LN-18 glioma cell line as a target for CD95 ligand-induced
Discussion
CD95/CD95 ligand interactions are crucial for the peripheral deletion of activated T cells (Alderson et al., 1995; Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995; Van Parijs et al., 1996). This is confirmed by autoimmune disorders which develop in mutant mice strains lacking functional CD95 (lpr) or CD95 ligand (gld). Here, we report that sera from MS patients with relapsing remitting disease contain elevated levels of soluble CD95 that inhibit CD95 ligand-induced apoptosis in
Acknowledgements
We thank Efi Faber for expert technical assistance. The work was supported by grants from the University of Tübingen (Fortüne 190, Interdisziplinäres Klinisches Forschungszentrum) and from the Deutsche Forschungsgemeinschaft (We 1502/5-1).
References (30)
- et al.
Cell death and birth in multiple sclerosis brain
J. Neurol. Sci.
(1997) - et al.
Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy
J. Neuroimmunol.
(1997) - et al.
Identification of soluble APO-1 in supernatants of human B and T cell leukemias
Blood
(1995) - et al.
Apoptosis in the nervous system in experimental allergic encephalomyelitis
J. Neurol. Sci.
(1991) - et al.
The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance
Immunity
(1996) - et al.
Fas ligand mediates activation-induced cell death in human T lymphocytes
J. Exp. Med.
(1995) - et al.
Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis
Ann. Neurol.
(1997) - et al.
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas
Nature
(1995) - et al.
Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
J. Immunol.
(1995) - et al.
Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis
J. Immunol.
(1996)
Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
Science
Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis
Nature Med.
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
Science
Autocrine T cell suicide mediated by APO-1/(Fas/CD95)
Nature
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain
J. Exp. Med.
Cited by (57)
Potential neurotoxic activity of diverse molecules released by astrocytes
2022, Brain Research BulletinCitation Excerpt :Notably, concentrations of these molecules correlate positively with the disease severity (Ding et al., 2018). Upregulated sFasL expression has also been measured in reactive astrocytes from the substantia nigra of PD patients (Ferrer et al., 2000) and the active lesions of MS patients (Zipp et al., 1999, 1998). Furthermore, mice with Fas mutations exhibit a milder progression of EAE.
JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response
2020, Clinical ImmunologyCitation Excerpt :In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, the number of CNS-infiltrating T cells increases dramatically during the acute phase but declines significantly during remission as a result of apoptotic cell death [8]. Several studies have demonstrated impaired apoptosis of T cells in patients with MS that may be associated with a persistence of myelin-activated T cells [9–11]. Of note, JNK-mediated phosphorylation of c-Jun promotes heterodimerization with c-Fos to form the AP-1 transcription factor.
Dual role of Response gene to complement-32 in multiple sclerosis
2013, Experimental and Molecular PathologyCitation Excerpt :Several studies have demonstrated impaired apoptosis of T cells in MS patients (Aktas et al., 2006; Sharief, 2000; Zipp et al., 1998). Furthermore, relapses may be associated with the persistent presence of myelin-activated T-cells resulting from impaired T-cell apoptosis (Aktas et al., 2006; Sharief, 2000; Zipp et al., 1998). T-cell apoptosis in both EAE and MS is in part regulated by the Fas-FasL system (Aktas et al., 2006), and ex vivo studies have demonstrated an increased resistance by T cells to Fas-mediated apoptosis during MS relapses (Okuda et al., 2006).
The CD4 <sup>+</sup> T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis
2012, Journal of NeuroimmunologyCitation Excerpt :Differences in the expression of Fas between healthy subjects and MS patients are controversial. Some authors found no differences (Zipp et al., 1998), while others showed a higher expression in MS patients (Ichikawa et al., 1996). We found a lower Fas expression in untreated MS patients in both CD4+ subsets, and this might be contributing to the pathogenesis of the disease by prolonging T-cell survival and promoting their migration to the CNS.
Apoptosis-related molecules in blood in multiple sclerosis
2008, Journal of NeuroimmunologyDetection of apoptotic cells in cerebrospinal fluid of patients suffering from neurological disease
2007, Journal of Neuroimmunology